PEPTIDE

Semaglutide

GLP-1 receptor agonist with extended half-life (~7 days); stimulates glucose-dependent insulin secretion and central appetite suppression.

BIOGATE · AMBER | POSTERIOR 29.7% | MW 4113.6 | 31AA

SEQUENCE

HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG

Modifications: AEEA-AEEA-γGlu-C18 lipid sidechain @ K20; Aib substitution @ position 2

PDA-V1 chain of custody

Outer hash

96939-ad097939c6398939df699939f899a93a11c9b93a2af9c93a4429d93

Merkle root

a043a4b79f43a324a243a7dda143a64a9c439e6b9b439cd89e43a1919d439ffe

Inputs

1940-d8501a40d9e31b40db761c40dd091d40de9c1e40e02f1f40e1c2204

TEE attestation

7-ab7cc9d79b7cb0a78b7c97777b7c7e476b7c65175b7c4be74b7c32b73b7c198

Living Outcome Oracle

± =10.8 ² =25.5 **P(success) = 29.7%** 95% CI [17.7%, 41.7%]

Suggested protocol

Metabolic Reset - GLP-1 Anchored

GRADE A

Type 2 diabetes adjunct + obesity (BMI e 30 or BMI e 27 with comorbidity)

Dose protocol redacted for researcher audience.

MONITORING ENDPOINTS

- HbA1c
- weight
- lipase
- CGM TIR
- Oura resting HR

Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

Citations

GRADE A

2021 · N Engl J Med

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

Wilding JPH et al.

DOI 10.1056/NEJMoa2032183